These variants included: TYMS (rs4544694 and rs11280056), TYMP (rs11479), DPYD (rs6737679 and rs1801265), GSTP1 (rs1695), MTHFR (rs1801131 and rs1801133), ERCC2 (rs13181), ABCB1 (rs1045642 and rs1128503), ABCC2 (rs717620), ABCC4 (rs9561778), and ABCG2 (rs2231142)
bimagrumab) may improve the body composition during WL and are in early phase clinical trials
Can lead to severe osteoarthritis if not managed
Genetic predisposition does not predict your exact response, but understanding your genetic background may support a more informed conversation with your provider about expected tolerability and dose progression
[5] [6] The actual side effect profile of any future oral formulation may differ from the injectable version